Table 2 Kaplan–Meier estimates of cumulative buprenorphine discontinuation overall and stratified by demographic characteristics

Overall

63.6% (62.7%, 64.5%)

80.5% (79.8%, 81.3%)

Age

 20–29

71.6% (69.0%, 74.3%)

86.2% (84.2%, 88.3%)

 30–39

65.5% (63.9%, 67.0%)

81.2% (79.9%, 82.4%)

 40–49

63.5% (61.2%, 65.9%)

79.6% (77.5%, 81.6%)

 50–59

59.7% (57.7%, 61.7%)

79.1% (77.4%, 80.8%)

 60–88

61.4% (59.6%, 63.1%)

79.2% (77.8%, 80.7%)

Gender

 Female

65.8% (62.8%, 68.7%)

81.2% (78.8%, 83.7%)

 Male

63.4% (62.5%, 64.3%)

80.5% (79.7%, 81.2%)

Race

 Asian

62.3% (50.1%, 74.5%)

73.9% (62.8%, 84.9%)

Black

71.1% (68.8%, 73.3%)

86.9% (85.1%, 88.6%)

 Other

64.6% (57.3%, 72.0%)

83.9% (78.1%, 89.8%)

 Unknown

66.8% (62.1%, 71.4%)

83.0% (79.2%, 86.7%)

 White

62.2% (61.3%, 63.2%)

79.4% (78.5%, 80.2%)